Fludarabine therapy in chronic lymphocytic leukemia (CLL)

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Fludarabine is a fluorinated adenine analogue resistant to deamination.
• Phase I trials indicated significant antitumor activity in lymphoid malignancies.
• Fludarabine has been utilized for chronic lymphocytic leukemia (CLL) treatment since 1985.

Purpose of the Study:

• To evaluate the efficacy and response rates of fludarabine in previously treated patients with CLL.
• To assess the impact of prior chemotherapy and patient characteristics on treatment outcomes.

Main Methods:

• A cohort of 68 previously treated CLL patients received fludarabine (25-30 mg/m2/day x 5 days every 3-4 weeks).
• Response was evaluated based on complete remission (CR) and partial remission (PR) criteria.
• Patient data including age, sex, prior regimens, Rai/Binet stage, and laboratory values were analyzed.

Main Results:

• Overall, 29% achieved CR and 28% achieved PR.
• Complete remission rates varied by site: blood (69%), liver (52%), spleen (55%), nodes (48%), and bone marrow (16%).
• Prior treatment number did not significantly impact response or survival; however, albumin, alkaline phosphatase, platelet, and hemoglobin levels were associated with survival.

Conclusions:

• Fludarabine shows considerable efficacy in treating relapsed or refractory CLL, with notable response rates across various disease sites.
• Bone marrow response was less pronounced compared to other sites.
• Prognostic factors like serum albumin and hemoglobin levels are important indicators of survival in fludarabine-treated CLL patients.